摘要:
There are provided according to the invention novel compounds of formula I wherein R1, R2 and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
摘要:
There are provided according to the invention novel compounds of formula (I) wherein R1, R2, and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
摘要:
A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.
摘要:
A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.
摘要:
The present invention is directed to a polymorph of a compound and salts of a compound and polymorphs thereof, which compound is an inhibitor of kinase activity.
摘要:
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
摘要:
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular Pl3-kinase activity.
摘要:
The invention provides a compound of formula (I) or a salt thereof: wherein R2 is H, C1-3alkyl, n-butyl, C1-2fluoroalkyl, cyclopropyl, cyclobutyl, (cyclopropyl)methyl-, —CN, or —CH2OH; R3 is inter alia optionally substituted C4-7cycloalkyl or an optionally substituted heterocyclic group (aa), (bb) or (cc); Ra is H, methyl or ethyl; Rb is H or methyl; R4 is H, methyl, ethyl, n-propyl, —C(O)-Me, or —C(O)—C1fluoroalkyl; and R5 is: —C(O)—(CH2)n—Ar, —C(O)-Het, —C(O)—C1-6alkyl, —C(O)—C1 fluoroalkyl, —C(O)—(CH2)2—C(O)—NR15bNR15b, —C(O)—CH2—C(O)—NR15bNR15b, —C(O)—NR15b—(CH2)m1—Ar, —C(O)—NR15b—Het, —C(O)—NR15b—C1-6alkyl, —C(O)—NR5aR5b, —S(O)2—(CH2)m2—Ar, —S(O)2-Het, —S(O)2—C1-6alkyl, or —CH2—Ar; or R4 and R5 taken together are —(CH2)p1—, —(CH2)2—X5—(CH2)2—, —C(O)—(CH2)p2—, —C(O)—N(R15)—(CH2)p3—; or NR4R5 is of sub-formula (y), (y1), (y2) or (y3). The invention provides the use of the compounds as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as COPD and the like.
摘要翻译:本发明提供式(I)化合物或其盐:其中R2是H,C1-3烷基,正丁基,C1-2氟烷基,环丙基,环丁基,(环丙基)甲基,-CN或-CH2OH; R3特别是任选取代的C 4-7环烷基或任选取代的杂环基团(aa),(bb)或(cc); Ra是H,甲基或乙基; Rb是H或甲基; R 4是H,甲基,乙基,正丙基,-C(O)-Me或-C(O)-C 1-6氟烷基; 并且R 5是:-C(O) - (CH 2)n -Ar,-C(O)-Het,-C(O)-C 1-6烷基,-C(O)-C 1氟代烷基,-C(O) (CH 2)2 -C(O)-NR 15 b N R 15 b,-C(O)-CH 2 -C(O)-NR 15 b NR 15 b,-C(O)-NR 15 b - (CH 2)m -Ar,-C(O) C(O)-NR 15 b -C 1-6烷基,-C(O)-NR 5 R 5a,-S(O)2 - (CH 2)m -Ar,-S(O)2 -Het,-S(O) 2-C 1-6烷基或-CH 2 -Ar; 或(R 4)和R 5和R 5一起为 - (CH 2)p1 - , - (CH 2)2 -X 5 - (CH 2)2 - , - - (CH 2)p3-; 或NR4R5为子式(y),(y1),(y2)或(y3)。 本发明提供了化合物作为IV型磷酸二酯酶抑制剂(PDE4)和/或用于治疗和/或预防炎性和/或过敏性疾病如COPD等的用途。